CJC-1295 + Ipamorelin Stack: The Gold Standard GH Protocol
Last updated: April 14, 2026 · 15 min read · Reviewed by Grey Peptides Editorial Board
TL;DR
The CJC-1295/Ipamorelin stack is the most widely prescribed growth hormone secretagogue combination in peptide therapy. It works by stimulating your pituitary gland to produce more natural growth hormone through two complementary pathways — CJC-1295 amplifies the GH release signal (GHRH pathway), while Ipamorelin adds a secondary trigger (ghrelin pathway). Together, they produce stronger, more sustained GH pulses than either compound alone, particularly during deep sleep. The standard protocol is 100 mcg CJC-1295 (no DAC) + 100–200 mcg Ipamorelin injected subcutaneously at bedtime on an empty stomach, 5 nights per week, for 3–6 months. Expected benefits include improved body composition (fat loss + lean mass), deeper sleep, enhanced recovery, and better skin quality.
→ This stack is rated "Strong Synergy" in our Interaction Checker.
→ Calculate exact dosing for both peptides with the Reconstitution Calculator.
Table of Contents
- Why This Is the Gold Standard
- How Each Peptide Works
- The Synergy Explained
- CJC-1295: DAC vs No DAC
- Complete Dosing Protocols (3 Tiers)
- Week-by-Week Schedule
- Reconstitution & Preparation
- Injection Timing & Food Rules
- What to Expect (Timeline)
- Side Effects & Management
- Adding a Third Compound
- Cost Breakdown
- Frequently Asked Questions
- Sources
Why This Is the Gold Standard
Of all available GH secretagogue combinations, CJC-1295/Ipamorelin has become the default recommendation at most peptide therapy clinics, and for good reason.
Dual-pathway stimulation. CJC-1295 and Ipamorelin activate growth hormone release through two different receptor systems on the pituitary gland. This produces a synergistic GH pulse greater than either compound achieves alone — analogous to pushing the gas pedal (GHRH) while also releasing the brake (ghrelin agonism).
Selectivity. Unlike older GH secretagogues such as GHRP-6 and GHRP-2, Ipamorelin is highly selective for growth hormone. It does not significantly increase cortisol, prolactin, or aldosterone at standard doses — a meaningful advantage for users concerned about stress hormones, sexual function, or water retention.
Natural pulsatility. Unlike exogenous HGH injection (which delivers a large, unphysiological spike of GH), this stack amplifies the body's own pulsatile GH release pattern. The pituitary releases GH in natural pulses, primarily during deep sleep. CJC-1295/Ipamorelin intensifies those pulses without eliminating the body's feedback mechanisms.
Clinical adoption. This combination is prescribed by a majority of anti-aging clinics, functional medicine practices, and peptide therapy providers in the US. While controlled clinical trial data for the specific combination is limited, the widespread clinical use and favorable anecdotal evidence base give it the largest real-world track record of any GH secretagogue stack.
How Each Peptide Works
CJC-1295 — The Amplifier
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic signal that tells the pituitary gland to release growth hormone. The native GHRH molecule has a very short half-life (minutes), making it impractical for therapy. CJC-1295 solves this through structural modifications that extend its duration of action.
Mechanism. CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary. This increases both the amplitude and duration of GH pulses. Think of it as turning up the volume on the signal your brain is already sending to release growth hormone.
Two forms exist:
- CJC-1295 (no DAC) — Also called Mod GRF 1-29. Half-life approximately 30 minutes. Produces discrete GH pulses.
- CJC-1295 with DAC — Drug Affinity Complex binds to albumin, extending the half-life to 6–8 days. Produces sustained, non-pulsatile GH elevation.
Most practitioners prefer the no-DAC form for this stack (see the DAC comparison section below). [1]
Ipamorelin — The Selective Trigger
Ipamorelin is a synthetic pentapeptide that mimics ghrelin — the "hunger hormone" — at the growth hormone secretagogue receptor (GHS-R) on the pituitary. It acts as a secondary trigger for GH release, working through a completely different receptor system than CJC-1295.
Mechanism. Ipamorelin binds GHS-R receptors on pituitary somatotrophs, stimulating GH release independently of GHRH signaling. At standard doses, it selectively triggers GH release without significantly affecting other pituitary hormones — a notable distinction from older ghrelin mimetics like GHRP-6, which also increase cortisol, prolactin, and appetite. [2]
Selectivity profile:
| Hormone | GHRP-6 Effect | GHRP-2 Effect | Ipamorelin Effect |
|---|---|---|---|
| Growth Hormone | ↑↑↑ | ↑↑↑ | ↑↑↑ |
| Cortisol | ↑↑ | ↑ | Minimal |
| Prolactin | ↑↑ | ↑ | Minimal |
| Appetite/Hunger | ↑↑↑ | ↑↑ | Mild ↑ |
This selectivity is Ipamorelin's key advantage. Elevated cortisol impairs recovery, disrupts sleep, and promotes fat storage. Elevated prolactin can cause sexual dysfunction and mood changes. By minimizing these off-target effects, Ipamorelin delivers GH stimulation without the hormonal side effects of its predecessors.
The Synergy Explained
The CJC-1295/Ipamorelin combination produces genuine biological synergy — the combined GH output exceeds what either compound produces individually. This isn't a marketing claim; it's a predictable result of activating two independent signaling pathways on the same target cell.
GHRH + Ghrelin = Amplified Pulse. The pituitary somatotroph cell receives two simultaneous signals to release GH. The GHRH signal (from CJC-1295) initiates GH synthesis and secretion. The ghrelin signal (from Ipamorelin) amplifies the release by modulating intracellular calcium signaling and removing inhibitory tone. Studies on GHRH + ghrelin agonist co-administration consistently show a synergistic GH response — 2 to 3 times greater than either stimulus alone. [3]
Complementary timing. CJC-1295 (no DAC) with its 30-minute half-life produces a sharp GH pulse that aligns with the natural nighttime GH surge. Ipamorelin's slightly longer duration extends and sustains the pulse. The result is a robust, extended GH release window during deep sleep — exactly when the body's repair and regeneration processes are most active.
Negative feedback preservation. Both peptides work upstream of GH itself. They stimulate the pituitary to produce more of its own growth hormone rather than introducing exogenous GH. This means the hypothalamic-pituitary feedback loop remains intact — somatostatin (the GH-inhibiting hormone) still functions, preventing runaway GH elevation. This is why GH secretagogues do not produce the acromegalic side effects (enlarged jaw, hands, feet) associated with chronic high-dose exogenous HGH abuse.
→ Compare this stack against Sermorelin, Tesamorelin, or MK-677 in the Comparison Tool.
CJC-1295: DAC vs No DAC
This is one of the most common questions in peptide therapy. The two forms of CJC-1295 have meaningfully different pharmacokinetics and practical implications.
CJC-1295 Without DAC (Mod GRF 1-29)
- Half-life: ~30 minutes
- Dosing: Daily (typically at bedtime)
- GH release pattern: Pulsatile (mimics natural physiology)
- Combined with Ipamorelin: Yes — standard pairing
- Pro: Preserves natural GH pulsatility, clean on/off effect
- Con: Requires daily injection
CJC-1295 With DAC
- Half-life: ~6–8 days (albumin binding)
- Dosing: 1–2 times per week
- GH release pattern: Sustained elevation (not pulsatile)
- Combined with Ipamorelin: Less commonly — the long half-life creates a constant GHRH signal that may blunt pulsatile response
- Pro: Fewer injections, convenience
- Con: Non-pulsatile GH release may be less physiological, potential for greater feedback suppression
Which Should You Choose?
Most practitioners recommend CJC-1295 without DAC (Mod GRF 1-29) for the Ipamorelin stack because it preserves pulsatile GH release — the pattern the body naturally uses. The sharp pulse at bedtime, amplified by Ipamorelin, closely mirrors the GH secretion pattern seen during normal deep sleep.
CJC-1295 with DAC may be appropriate for individuals who strongly prefer fewer injections and are willing to accept a less physiological GH release pattern. Some practitioners use the DAC form for its convenience, particularly in patients who struggle with daily injection compliance.
→ For the full comparison, see our article: CJC-1295 DAC vs No DAC.
Complete Dosing Protocols (3 Tiers)
Beginner Protocol (Conservative Start)
Start with a lower dose to assess tolerance and response before increasing.
| Peptide | Weeks | Dose | Frequency | Timing |
|---|---|---|---|---|
| CJC-1295 (no DAC) | 1–2 | 50 mcg | Daily | Bedtime, empty stomach |
| Ipamorelin | 1–2 | 100 mcg | Daily | Bedtime, empty stomach |
| CJC-1295 (no DAC) | 3–12 | 100 mcg | Daily | Bedtime, empty stomach |
| Ipamorelin | 3–12 | 100 mcg | Daily | Bedtime, empty stomach |
Total duration: 12 weeks (3 months), then 4 weeks off, then reassess.
Standard Protocol (Most Common)
The protocol prescribed by most peptide therapy clinics.
| Peptide | Dose | Frequency | Timing |
|---|---|---|---|
| CJC-1295 (no DAC) | 100 mcg | 5–7 nights/week | Bedtime, empty stomach |
| Ipamorelin | 200 mcg | 5–7 nights/week | Bedtime, empty stomach |
Total duration: 3–6 months continuously, then 4–8 weeks off. Many clinics run this on a 5-nights-on, 2-nights-off schedule (weeknights on, weekends off) to provide periodic rest for pituitary sensitivity.
Advanced Protocol (Split Dosing)
For individuals seeking maximum GH optimization. Splitting the dose creates two GH pulses per day instead of one.
| Peptide | Dose (Morning) | Dose (Bedtime) | Timing |
|---|---|---|---|
| CJC-1295 (no DAC) | 100 mcg | 100 mcg | Empty stomach (fasted AM + bedtime) |
| Ipamorelin | 100 mcg | 200 mcg | Empty stomach (fasted AM + bedtime) |
Note: The bedtime dose is larger because the natural GH pulse during sleep is the primary target. The morning dose adds an additional recomposition benefit but must be taken in a fasted state (before breakfast) and followed by at least 30 minutes of fasting before eating.
→ Build your personalized CJC-1295/Ipamorelin schedule with the Protocol Builder.
Week-by-Week Schedule
Weeks 1–2: Adaptation
Begin with the conservative or standard dose. The body adjusts to increased GH secretion. Some users notice improved sleep quality within the first few days — this is often the first observable effect. Mild water retention is common and typically resolves by week 3–4.
Weeks 3–4: Early Response
Sleep quality improvements become more consistent. Recovery from exercise may feel noticeably faster. Some users report more vivid dreams. Skin may appear slightly more hydrated. Fat loss and body composition changes are not yet visible.
Weeks 5–8: Visible Changes
Body composition shifts begin to appear — subtle fat reduction (particularly in the midsection), improved muscle tone, better workout performance. Recovery between training sessions continues to improve. Skin quality improvements become noticeable (increased collagen production from sustained GH elevation).
Weeks 9–12: Full Effect
Peak body composition benefits emerge. Fat loss becomes clearly visible if combined with appropriate nutrition and training. Lean mass preservation or increase is apparent. Joint comfort may improve (GH supports cartilage health). Hair and nail growth may accelerate.
Months 4–6: Sustained Optimization
Continued gradual improvement in body composition. Full recomposition benefits are visible — the combination of fat reduction and lean mass maintenance creates a meaningfully different physique. Benefits in recovery, sleep, and skin quality are well-established and consistent.
Reconstitution & Preparation
Both peptides follow the standard reconstitution process detailed in our How to Reconstitute Peptides guide.
CJC-1295 (no DAC)
| Parameter | Value |
|---|---|
| Common vial size | 2 mg or 5 mg |
| Recommended BAC water | 2 mL (for 5 mg vial) |
| Concentration | 2.5 mg/mL = 2,500 mcg/mL |
| 100 mcg dose = | 4 units on U-100 insulin syringe |
| Doses per 5 mg vial | 50 doses (at 100 mcg) |
Ipamorelin
| Parameter | Value |
|---|---|
| Common vial size | 5 mg |
| Recommended BAC water | 2 mL |
| Concentration | 2.5 mg/mL = 2,500 mcg/mL |
| 100 mcg dose = | 4 units on U-100 insulin syringe |
| 200 mcg dose = | 8 units on U-100 insulin syringe |
| Doses per 5 mg vial | 25 doses (at 200 mcg) |
Can I Mix Both in One Syringe?
Some practitioners draw both peptides into a single insulin syringe to reduce the number of injections. Draw CJC-1295 first, then draw Ipamorelin into the same syringe. Both are stable in the same solution for the brief period between drawing and injecting. However, never pre-mix the two vials — draw from separate vials into one syringe immediately before injection.
→ Enter your specific vial sizes for exact unit calculations at the Reconstitution Calculator.
Injection Timing & Food Rules
Timing is critical for GH secretagogues — more so than for repair peptides like BPC-157 or TB-500.
The Empty Stomach Rule
Insulin and blood glucose suppress growth hormone release. Food intake — particularly carbohydrates and fats — triggers insulin secretion, which directly inhibits the GH pulse that CJC-1295/Ipamorelin is designed to produce. Injecting after a meal significantly reduces the stack's effectiveness.
The rule: Wait at least 2 hours after your last meal before injecting. After injecting, wait at least 30 minutes before eating (though most users inject at bedtime and don't eat until morning, making this irrelevant).
What about protein? Even protein stimulates some insulin release. While a small protein-only snack is less disruptive than a full meal, the cleanest results come from injecting in a truly fasted state.
Bedtime Injection Rationale
The largest natural GH pulse occurs during the first cycle of deep (slow-wave) sleep, typically 60–90 minutes after falling asleep. By injecting CJC-1295/Ipamorelin 15–30 minutes before bed, the peptides reach peak plasma concentration just as the natural GH pulse begins — amplifying it at the optimal moment.
This is also why the stack improves sleep quality: elevated GH during deep sleep enhances the restorative aspects of that sleep stage, creating a positive feedback loop.
Sample Evening Timeline
- 7:00 PM — Finish dinner
- 9:15 PM — Inject CJC-1295/Ipamorelin (2+ hours after eating)
- 9:30 PM — Begin bedtime routine
- 10:00 PM — Lights out
- 11:00–11:30 PM — Deep sleep begins; amplified GH pulse occurs
Side Effects & Management
CJC-1295/Ipamorelin is generally well-tolerated at standard doses. Most side effects are mild, transient, and dose-dependent.
Common (Experienced by >10% of Users)
Water retention. Mild puffiness, typically in the hands, face, or ankles, most noticeable in weeks 1–3. GH promotes sodium and water reabsorption in the kidneys. Usually resolves as the body adjusts. Manage with adequate hydration and moderate sodium intake.
Increased hunger. Ipamorelin's ghrelin-mimetic activity can increase appetite, though much less than GHRP-6. Usually mild. Can be managed by injecting at bedtime (sleep through the hunger window).
Flushing or warmth. A brief sensation of warmth or facial flushing within minutes of injection. Harmless, typically resolves in 5–15 minutes. Related to GH-releasing peptide activity.
Occasional (5–10% of Users)
Tingling or numbness in extremities. Particularly in the hands or fingers. May mimic carpal tunnel symptoms. Related to GH-induced fluid retention compressing peripheral nerves. Dose reduction usually resolves it.
Vivid dreams. Commonly reported and likely related to enhanced deep sleep. Not harmful.
Headache. Usually mild and transient. More common in the first week.
Rare (<5% of Users)
Joint stiffness. At higher doses, GH-mediated fluid retention and cartilage stimulation can cause temporary joint discomfort. Dose reduction resolves this.
Elevated blood glucose. Growth hormone induces insulin resistance at higher levels. Individuals with pre-diabetes or insulin resistance should monitor fasting glucose. This is a dose-dependent effect and is more relevant at supraphysiological GH levels.
Adding a Third Compound
The CJC-1295/Ipamorelin base can be extended with additional peptides depending on your goals.
For Tissue Repair: Add BPC-157
Adding BPC-157 (250–500 mcg 2x daily) to the GH secretagogue base combines growth hormone optimization with targeted tissue repair. BPC-157's upregulation of GH receptors in connective tissue may enhance the reparative effects of the increased GH levels. This combination is popular among athletes and active individuals recovering from injuries.
For Fat Loss: Add AOD-9604
Adding AOD-9604 (250 mcg in the morning, fasted) creates a dual-mechanism fat loss approach — GH-driven lipolysis from CJC-1295/Ipamorelin at night, plus direct lipolytic fragment activity from AOD during the day.
For Anti-Aging: Add GHK-Cu
Adding GHK-Cu (100–200 mcg daily) extends the protocol's benefits to skin, hair, and extracellular matrix remodeling. The combination of elevated GH (collagen synthesis) and GHK-Cu (copper-mediated ECM repair) produces comprehensive anti-aging benefits.
→ Check any three-compound combination for interactions and timing conflicts at the Interaction Checker.
Cost Breakdown
Costs vary significantly between compounding pharmacies, peptide clinics, and research suppliers. The following estimates are based on 2026 US compounding pharmacy pricing.
Standard Protocol Monthly Cost
| Item | Quantity/Month | Est. Cost |
|---|---|---|
| CJC-1295 (no DAC), 5 mg vial | ~1 vial | $60–$100 |
| Ipamorelin, 5 mg vial | ~1.5 vials | $80–$140 |
| Insulin syringes (100-count box) | ~1/3 box | $5–$8 |
| Alcohol swabs | ~60 | $3–$5 |
| Bacteriostatic water, 30 mL | Shared across vials | $8–$12 |
| Monthly total | $156–$265 |
Over a 6-month protocol, total cost typically falls between $900 and $1,600 — significantly less than exogenous HGH ($600–$2,000/month) or GLP-1 agents ($800–$1,500/month at retail).
→ Get a personalized cost estimate for your exact protocol at the Cost Calculator.
Frequently Asked Questions
How long does it take for CJC-1295/Ipamorelin to work? Sleep quality improvements are often noticed within the first 1–2 weeks. Body composition changes become visible at 6–12 weeks. Full recomposition benefits emerge over 3–6 months. This is not a rapid-results protocol — it works gradually by optimizing your body's own hormone production.
Can I use CJC-1295 or Ipamorelin alone? Yes, either can be used independently. However, the combination produces significantly greater GH elevation than either compound alone (synergistic, not additive). Most practitioners recommend the combination unless there is a specific reason to use one compound.
Will this shut down my natural GH production? No. Unlike exogenous HGH, which suppresses pituitary GH production through negative feedback, GH secretagogues work by stimulating the pituitary to produce more of its own GH. The hypothalamic-pituitary feedback loop remains intact. After discontinuation, GH levels return to baseline — they do not drop below baseline.
Is this stack safe for women? Yes. The protocol is used by both men and women at the same doses. Women may experience slightly different body composition responses (less muscle hypertrophy, similar fat loss patterns).
Can I take this with TRT (testosterone replacement therapy)? Yes, and it's a common combination. GH and testosterone have complementary effects on body composition. However, both affect metabolic parameters, so regular blood work is advisable.
Do I need to cycle off? Most protocols include periodic breaks (4–8 weeks off after 3–6 months on) to maintain pituitary sensitivity. Some practitioners run continuous protocols with periodic blood work monitoring. There is no definitive evidence establishing the optimal cycling approach.
What blood work should I monitor? At minimum: IGF-1 (the primary marker of GH activity), fasting glucose and HbA1c (to screen for insulin resistance), and a comprehensive metabolic panel. Check baseline levels before starting, then recheck at 8–12 weeks.
Should I inject 5 or 7 nights per week? Both approaches are used. The 5-on/2-off schedule provides periodic pituitary rest days that may help maintain receptor sensitivity over long protocols. The 7-night schedule maximizes consistency. Most clinics start with 5 nights and adjust based on blood work and response.
Related Tools & Guides
- Reconstitution Calculator — Calculate exact dose units for both peptides
- Protocol Builder — Build the complete stack schedule with timing
- Comparison Tool — Compare this stack vs Sermorelin, Tesamorelin, MK-677
- Interaction Checker — Verify compatibility when adding third compounds
- Cost Calculator — Estimate your monthly and total protocol cost
- Half-Life Visualizer — See CJC-1295 and Ipamorelin's plasma curves
Related Articles
- Best Peptides for Muscle Growth in 2026
- Best Peptides for Fat Loss: A Research-Based Guide
- CJC-1295 DAC vs No DAC: What's the Difference?
- CJC-1295 vs Sermorelin: Which GH Peptide to Choose
- Ipamorelin vs Sermorelin: Head-to-Head
Sources
- Teichman, S. L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. PMID: 16352683
- Raun, K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. PMID: 9849822
- Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329. PMID: 9893709
- Anderson, L. L. et al. (2004). Synergistic interaction of GHRH and GHRP on growth hormone secretion in cattle. Domestic Animal Endocrinology, 27(1), 7–21. PMID: 15219911
- Svensson, J. et al. (1999). Effects of growth hormone and its secretagogues on body composition. Endocrine, 14(1), 35–39. PMID: 10536654
- Nass, R. et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601–611. PMID: 18981485
- Ionescu, M. & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. PMID: 17018654
Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Growth hormone secretagogues are not FDA-approved for general anti-aging, body composition, or performance purposes. Peptide therapy should be pursued under the supervision of a licensed healthcare professional with regular blood work monitoring. Do not begin any GH-modulating protocol without medical guidance.
© 2026 GreyPeptides.com — All rights reserved.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.